S
SkinCure Oncology
Provides dermatology services
About SkinCure Oncology
SkinCure Oncology, founded in 2016 by Kerwin Brandt and Steven Scott, provides a comprehensive solution for treating non-melanoma skin cancer. The company's inception traces back to a co-founder's graduate thesis on superficial radiation treatment as a viable alternative to Mohs surgery. Brandt, the CEO, brings over 25 years of experience in healthcare financing and ventures, having previously led Accelitech, which was instrumental in launching the CyberKnife® platform. Scott, the Chief Strategy & Innovation Officer, has an extensive background in healthcare management, including as COO for a large dermatology practice and various roles in oncology direction.
The company's core offering is Image-Guided Superficial Radiotherapy (IG-SRT), marketed to patients as the GentleCure™ Experience. This technology serves as a non-surgical alternative for treating basal cell and squamous cell carcinomas, which affect approximately 3.3 million individuals in the U.S. annually. The IG-SRT system uses high-frequency ultrasound for imaging, allowing clinicians to see the lesion, measure it, and deliver a precise, low-level dose of X-rays to destroy cancer cells without surgical cutting. This approach reports a cure rate of over 99% and offers superior cosmetic outcomes compared to surgery, with no need for reconstructive procedures.
SkinCure Oncology operates on a turnkey business model, partnering with dermatology practices and Mohs surgeons across the United States. The company provides a comprehensive package that includes the IG-SRT equipment, regulatory assistance, room renovation, installation, and highly trained radiotherapy staff. This allows physician partners to offer cancer center-level care directly in their offices. This model has enabled rapid expansion, growing from 10 practice partners in 2017 to approximately 500 by late 2024. In October 2024, an affiliate of H.I.G. Capital made a significant investment to acquire the company, aiming to accelerate growth and expand the GentleCure brand, while the existing leadership team remains in place with a significant ownership stake.
Source: Dealroom company dataNews
Open roles
SkinCure Oncology in the Burr Ridge ecosystem
The SkinCure Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Seacoast Capital Partners
HIG Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SkinCure Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SkinCure Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


